Ekf Diagnostics Share Price (EKF)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ekf Diagnostics	LSE:EKF	London	Ordinary Share	GB0031509804	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.90p	+2.43%	37.90p	71,568	12:02:26

Bid Price		Offer Price	High Price	Low Price	Open Price
36.50p		37.80p	37.90p	37.90p	37.90p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	41.58	4.31	59.00	0.6	173.4

Related Shares
Smith & Nephew (SN.), NMC Health (NMC), Physiomics (PYC), Widecells (WDC)

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics News

Date	Time	Source	Headline
19/9/2018	10:25	ALNC	EKF Diagnostics Interim Profit Grows As Costs Fall Despite Revenue Dip
19/9/2018	07:58	ALNCF	Alliance News Flash Headline
19/9/2018	07:00	UKREG	EKF Diagnostics Holdings PLC Half-year Report
17/9/2018	12:21	UKREG	EKF Diagnostics Holdings PLC Notice of Results
31/8/2018	14:21	ALNC	EKF Diagnostics Looks To Investors For Possible Renalytix Listing (ALLIPO)
31/8/2018	14:00	UKREG	EKF Diagnostics Holdings PLC Update regarding proposed IPO of Renalytix AI
16/8/2018	07:01	UKREG	EKF Diagnostics Holdings PLC Holding(s) in Company
09/8/2018	10:34	ALNC	EKF Diagnostics Signs American Distribution Deal With McKesson
09/8/2018	09:14	DJN	EKF Diagnostics 1st Half Slightly Ahead of Expectations, Signs U.S...
09/8/2018	07:14	UKREG	EKF Diagnostics Holdings PLC Trading update

More Ekf Diagnostics News

Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date	Time	Title	Posts
21/9/2018	07:36	EKF Diagnostics - Growth by acquisition, expertise and special relationships	1,272
27/7/2011	06:35	EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh	7
25/7/2011	14:22	EKF Diagnostics	209
13/7/2010	21:15	EFK DIAGNOSTICS	6

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
11:41:46	37.15	20,000	7,430.00	O
11:02:37	37.15	50,000	18,575.00	O
07:17:52	37.00	318	117.66	O
07:01:15	37.90	1,250	473.75	AT
2018-09-24 14:20:57	37.18	25,000	9,295.00	O

View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Date	Subject
25/9/2018 09:20	Ekf Diagnostics Daily Update: Ekf Diagnostics is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 37p. Ekf Diagnostics has a 4 week average price of 36.10p and a 12 week average price of 30p. The 1 year high share price is 41.10p while the 1 year low share price is currently 22p. There are currently 457,632,749 shares in issue and the average daily traded volume is 104,183 shares. The market capitalisation of Ekf Diagnostics is £173,442,811.87. Read Full Thread Reply
09/4/2018 09:28	wan: N+1 Singer analyst Chris Glasper has published commentary today in which he described news from EKF of FDA 510k approval and CLIA Waiver as “very positive news” and asserts that “the potential opportunity is material for EKF”, with a “$35m+ market for point of care testing in the US to go at”. Forecasts remain unchanged at the moment but he writes: “We make no changes to our estimates, pending confirmation of the commercial strategy, which we expect in the coming months. We continue to see meaningful upside to the current share price on this and other opportunities in the pipeline.” N+1 Singer currently forecast £43.4m revenue for 2018, adj EBITDA of £10m and £7.5m adj PBT. For 2019 these rise to £44.7m, adj EBITDA of £10.8m and adj PBT of £8.0m. (END) Indeed I concur ;-) I also see material upside. Read Full Thread Follow Reply
05/10/2016 09:59	interstellar: Az. Sure. And Tesco is a case in point. Lots of people got a surprise when some of their hidden accounting practises came to light. It took a whistle blower to point them out. I'm just trying to point out that headline numbers when expressed in certain ways can be deceiving. The track record so far for EKF is not great despite much promise. Now they are meant to be on firmer ground with a clear sight of the goals (if not the end of the tunnel) but there is a notable absence of activity in the share price going north, or newsflow come to that, to underline these favourable expectations. Read Full Thread Follow Reply
20/7/2016 11:58	andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward. Read Full Thread Follow Reply
06/7/2016 07:16	wan: An encouraging and upbeat Trading Update today, as well as clarifying that Brexit will have no effect on sales - "the Board notes that it does not anticipate any impact to sales from the forthcoming decoupling of the United Kingdom from the European Union. EKF sales into EU countries are derived entirely from offices within the EU and US, with no such sales made from the UK and therefore global sales are not expected to be impacted." http://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Trading-Update/71899624 Read Full Thread Follow Reply
12/4/2016 09:44	cisk: With his shareholding and loan to the company I don't think it's over with him at all, in fact I'm surprised he resigned. I'm also surprised with the share price reaction today - i.e. it's gone up. It's very clear there's an awful lot of work to do, both in terms of restoring management credibility and actually making a proper profit. Currently all the share price offers is hope. My fingers have been burnt on this one in the past, I'd rather buy back at a higher price, after tangible evidence of progress on the bottom line is evident. Read Full Thread Follow Reply
04/4/2016 11:09	wan: I am not suggesting that the postponement of the Results by a week is anything to do with the following, it's just food for thought; Some might recall that as reported by EKF, http://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Strategic-Update/69002271 RZ is also currently Chairman and Chief Executive Officer of Lumira Holdings Ltd. But what interested me more was the connected business Lumira Diagnostics Ltd. I further noticed the following job vacancy description, which was posted in December 2015 (no other job listings state that Multi-Sense is a subsidiary of Lumira) - Engineering And Manufacturing Manager in Lumira Diagnostics (UK) Multi-Sense, a subsidiary of Lumira, are a young and energetic company developing revolutionary and flexible assay platform technologies that will transform In Vitro Diagnostic testing and provide next generation healthcare. The company was founded in 2009 and is located at our newly built facility in Stirling. We are looking for a proactive, talented, focused and enthusiastic individual who can make a significant contribution to the continued growth and success of our company. (end) Revolutionary and transforming have big meanings, but are obviously just words at present and there may be no connection and just a typo. RZ is not listed as a director at Multi-Sense, however, his fellow directors at Lumira, Dr David Scott and Dr Jerome Francis Francis Mcaleer, are both directors at Muti-Sense. Very recently, and apparently as a result of growth, Multi-Sense Technologies have posted quite a few vacancies - March 2016: Due to continued growth, we are currently recruiting for a variety of roles as shown below: http://mst-uk.com/News.html Multi-Sense and Lumira are still listed as a private independent companies, but that does not mean that that is still the case as Companies House will get updated at the next filing date. I also noticed that the following individual has apparently done some work for Lumira - Richard R. Kelly Rich concentrates on cross-border and domestic M&A representation and corporate fiduciary counseling. He co-heads the firm’s International Practice. Lumira Holdings Ltd in its expatriation to the U.K. and in connection with its private placements and acquisitions of connected health companies. https://www.mintz.com/professionals/detail/name/richard-r-kelly RZ has quite a bit of history and connection with companies/deals in Scotland. Thus it will be interesting to see what materializes, or indeed if there is any connection formed with Lumira and/or multi-Sense. Read Full Thread Follow Reply
06/11/2015 16:11	cisk: all, tbh I would expect the likes of Baines et al to be buying shares in the market at the current level. If they can't announce sales etc then thats the only option to shore up confidence. Assuming they could of course... I'm thoroughly disappointed in this whole episode - after hearing them discuss the tech, pipeline and opportunities at length many times I'm seriously surprised we're where we are. The much-trumpeted sales to Mexico for example have not been announced. Nor do I hold out hope of RZ coming to the rescue at a price anywhere near what we would find appetising. He didn't make a fortune by being generous to shareholders of companies he wants to acquire. Wan, I know you thought 10p was wide of the mark, but if RZ spots an opportunity to buy the whole lot, spin off the molecular division on nasdaq in 6 months and develop the diagnostic side, he'll take it and pay the minimum to do so. And the institutions that bought around 40p if memory serves would probably be glad to get this company off their books at 10p as it's unlikely they could shift any serious volume of stock without collapsing the share price even more from current levels. what the company is actually worth is anyone's guess. Probably what RZ is prepared to pay as so far he looks like the only person who might buy the company. Read Full Thread Follow Reply
02/11/2015 10:59	kestelmill: My hunch is this: -RZ sees this company as his next vehicle -RZ strategy will be as per his normal strategy - become major global Dx player via acquisition -RZ is fairly well aligned with DE/JB on strategy -Hence when DE/JB were challenged by major shareholders they saw RZ chairmanship as a good fall back option -They now have carte blanche to progress, at least for the time being. A bit like when a football club appoints a new manager - they've got a reasonable period to succeed. -Major shareholders will realise this and if it doesn't fit with their investment approach (risk, etc) they will bail out. This is happening now hence share price going down. -I wouldn't be surprised if RZ becomes CEO. It depends on his relationship with JB and how many shares he buys. -All depends on RZ now. Not such a bad horse to back but share price likely to go down before it recovers. Read Full Thread Follow Reply
25/6/2015 08:59	cisk: Morning Wan Agree - Mgt will be judged on next month's update - but as we both know, it takes a long time to gain any sort of traction in diagnostics - in fact anything healthcare related - as my small holding in Deltex will attest to! Very interesting news re: Alere; given the already strong relationship between them and Ron's shareholding in both companies it would not be a surprise. However I'm in it for the long term and believe that the share price can be at multiples of its current level, so personally I wouldn't want to see them taken over at a price anywhere near the current share price. Hopefully patience will be my biggest ally... Read Full Thread Follow Reply
08/5/2014 10:20	totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers? Read Full Thread Follow Reply

Ekf Diagnostics share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:30 V: D:20180925 12:37:45